[go: up one dir, main page]

NO20043904L - Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens - Google Patents

Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens

Info

Publication number
NO20043904L
NO20043904L NO20043904A NO20043904A NO20043904L NO 20043904 L NO20043904 L NO 20043904L NO 20043904 A NO20043904 A NO 20043904A NO 20043904 A NO20043904 A NO 20043904A NO 20043904 L NO20043904 L NO 20043904L
Authority
NO
Norway
Prior art keywords
polyvinylpyrrolidone
excipient
active ingredient
dosage form
oral dosage
Prior art date
Application number
NO20043904A
Other languages
English (en)
Other versions
NO332844B1 (no
Inventor
Klaus Eistetter
Rango Dietrich
Hartmut Ney
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27758398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20043904(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002107160 external-priority patent/DE10207160A1/de
Publication of NO20043904L publication Critical patent/NO20043904L/no
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of NO332844B1 publication Critical patent/NO332844B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20043904A 2002-02-20 2004-11-22 Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens, anvendelse derav og fremgangsmåte for fremstilling av det samme. NO332844B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02003811 2002-02-20
DE2002107160 DE10207160A1 (de) 2002-02-20 2002-02-20 Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
PCT/EP2003/001650 WO2003070279A1 (en) 2002-02-20 2003-02-19 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Publications (2)

Publication Number Publication Date
NO20043904L true NO20043904L (no) 2004-11-11
NO332844B1 NO332844B1 (no) 2013-01-21

Family

ID=27758398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043904A NO332844B1 (no) 2002-02-20 2004-11-22 Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens, anvendelse derav og fremgangsmåte for fremstilling av det samme.

Country Status (33)

Country Link
US (11) US7951397B2 (no)
EP (2) EP2258394B1 (no)
JP (1) JP4163120B2 (no)
KR (2) KR101386843B1 (no)
CN (2) CN102764242B (no)
AR (1) AR038527A1 (no)
AT (1) ATE550038T1 (no)
AU (1) AU2003206924B2 (no)
BR (1) BR0307739A (no)
CA (1) CA2475923C (no)
CY (2) CY1112811T1 (no)
DK (2) DK1478399T3 (no)
EA (1) EA008219B1 (no)
EC (1) ECSP045238A (no)
ES (2) ES2384378T3 (no)
GE (1) GEP20074079B (no)
IL (3) IL162843A0 (no)
IS (1) IS7410A (no)
MA (1) MA27100A1 (no)
ME (1) ME00566A (no)
MX (1) MXPA04005759A (no)
MY (1) MY140561A (no)
NO (1) NO332844B1 (no)
NZ (1) NZ535197A (no)
PE (1) PE20030823A1 (no)
PL (1) PL226401B1 (no)
PT (2) PT1478399E (no)
RS (1) RS52548B (no)
SI (2) SI2258394T1 (no)
TN (1) TNSN04124A1 (no)
TW (1) TWI363636B (no)
UA (1) UA84266C2 (no)
WO (1) WO2003070279A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
DE10350528A1 (de) * 2003-10-29 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
SI2366393T1 (sl) * 2005-04-19 2013-12-31 Takeda Gmbh Roflumilast za zdravljenje pljučne hipertenzije
SI2359826T1 (sl) 2006-07-05 2014-02-28 Takeda Gmbh Kombinacija HMG-CoA reduktaznega inhibitorja rosuvastatina s fosfodiesteraznim 4 inhibitorjem, kot je roflumilast, roflumilast-N-oksid, za zdravljenje vnetnih pljučnih bolezni
US20110160213A1 (en) * 2007-02-01 2011-06-30 Glenmark Pharmaceuticals, S.A. Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
HRP20171384T4 (hr) * 2007-03-29 2024-02-16 Daiichi Sankyo Company, Limited Farmaceutski pripravak
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
US20130299501A1 (en) 2010-10-22 2013-11-14 Daewoo Shipbuilding & Marine Engineering Co., Ltd. Storage container for liquefied natural gas
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
TWI578988B (zh) 2011-08-10 2017-04-21 第一三共股份有限公司 含二胺衍生物之醫藥組成物
CN102274222B (zh) * 2011-08-18 2013-04-10 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特药物组合物及其制备方法
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
SG10201605251VA (en) * 2011-12-27 2016-08-30 Celgene Corp Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
CN103446070B (zh) * 2012-05-31 2016-06-22 天津康鸿医药科技发展有限公司 一种罗氟司特固体速释制剂及其制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103565806A (zh) * 2012-07-31 2014-02-12 江苏柯菲平医药有限公司 一种罗氟司特口服制剂及其制备方法
DK2892540T3 (en) * 2012-09-06 2018-11-19 Mcpharma Biotech Inc TREATMENT OF DIARRES AND DRAWN DIARRES WITH RESISTANT POTATO STARCH
CN102871976A (zh) * 2012-09-29 2013-01-16 华润赛科药业有限责任公司 一种含有罗氟司特作为活性成分的片剂及其制备方法
CN102949370B (zh) * 2012-11-27 2018-05-04 贵州信邦制药股份有限公司 一种罗氟司特片及其制备方法和检测方法
CN103127011B (zh) * 2012-12-27 2014-11-26 深圳万乐药业有限公司 罗氟司特片及其制备方法
CN103330689A (zh) * 2013-03-31 2013-10-02 北京万全德众医药生物技术有限公司 一种含有罗氟司特的口腔崩解片
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
EP3043798A4 (en) * 2013-09-13 2017-04-12 Hetero Research Foundation Pharmaceutical compositions of roflumilast and process for preparation thereof
WO2015132708A1 (en) * 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016016824A1 (en) 2014-07-29 2016-02-04 Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
JP5938537B1 (ja) 2014-10-24 2016-06-22 久光製薬株式会社 プロドラッグ
WO2016120746A1 (en) * 2015-01-29 2016-08-04 Micro Labs Limited A pharmaceutical composition comprising roflumilast
CN106176639A (zh) * 2015-04-30 2016-12-07 四川科伦药物研究院有限公司 一种制备罗氟司特片的方法
RU2659206C2 (ru) * 2016-04-14 2018-06-28 Общество с ограниченной ответственностью "Технофарм" Состав и способ промышленного производства тритурации дигоксина (варианты)
CN106139161A (zh) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 一种罗氟司特包合物及其固体制剂
JP7019978B2 (ja) * 2017-06-30 2022-02-16 富士電機株式会社 設備管理システム、設備管理方法およびプログラム
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111643470A (zh) * 2020-04-30 2020-09-11 山东希尔康泰药业有限公司 罗氟司特薄膜包衣片制备工艺
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243797B1 (en) 2020-11-16 2026-02-25 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
IL319352A (en) 2022-09-15 2025-05-01 Arcutis Biotherapeutics Inc Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4024240A (en) * 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
NZ196700A (en) * 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
DE3308239A1 (de) 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
GB8415540D0 (en) * 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
JPS61205208A (ja) 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS61205208U (no) 1985-06-12 1986-12-24
JPS625966A (ja) * 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (en) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
JPH0249720Y2 (no) 1986-05-08 1990-12-27
US5286494A (en) 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4791117A (en) * 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
EP0266890A1 (en) 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US4831041A (en) * 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
KR890701585A (ko) 1987-07-16 1989-12-21 헤르베르크 슈키·울리히 볼프 새로운 디아졸
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5011843A (en) 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
EP0368158A1 (de) 1988-11-07 1990-05-16 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Imidazopyridine
KR900014376A (ko) 1989-03-13 1990-10-23 후지사와 토모키치로 이미다조 피리딘 화합물 및 그것의 제조방법
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
WO1990012789A1 (de) 1989-04-17 1990-11-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3943385A1 (de) 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
US5215999A (en) * 1990-03-28 1993-06-01 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative and antiulcer agent containing said quinoline derivative
JP2851117B2 (ja) 1990-03-30 1999-01-27 日清製粉株式会社 インドール誘導体およびそれらを有効成分とする抗潰瘍薬
JP2816227B2 (ja) 1990-03-30 1998-10-27 日清製粉株式会社 抗潰瘍薬
WO1991017164A1 (de) 1990-04-27 1991-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (de) 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazine
ATE168101T1 (de) 1990-10-16 1998-07-15 Byk Gulden Lomberg Chem Fab Arylpyridazinone
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
HUT67609A (en) 1991-01-29 1995-04-28 Smithkline Beecham Intercredit Salts of a 4-amino-3-acyl-quinoline derivative, their preparation and pharmaceutical compositions comprising them
SE9100920D0 (sv) * 1991-03-27 1991-03-27 Astra Ab New active compounds
WO1992019602A1 (de) 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
ATE245023T1 (de) * 1991-05-28 2003-08-15 Mcneil Ppc Inc Kaubare zusammensetzung zur arzneimittelfreisetzung
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
DE59209687D1 (de) * 1991-10-25 1999-06-02 Byk Gulden Lomberg Chem Fab Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
GB9126438D0 (en) 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
GB9200607D0 (en) 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
GB9201693D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
AU3481593A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
JP3523275B2 (ja) 1992-03-26 2004-04-26 東光薬品工業株式会社 貼付剤
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
JP3634861B2 (ja) 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
DK0652868T3 (da) 1992-07-28 2005-02-14 Aventis Pharma Ltd Hæmmere af c-AMP-phosphodiesterase
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP3480575B2 (ja) 1993-04-22 2003-12-22 アルタナ ファルマ アクチェンゲゼルシャフト 新規ピリジニウム塩及びヘリコバクター細菌に基因する疾患を治療するための医薬品
DE4314963A1 (de) 1993-05-06 1994-11-10 Bayer Ag Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine
US5556863A (en) 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
ATE217612T1 (de) 1993-07-02 2002-06-15 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
EP0719561A4 (en) 1993-08-10 1997-07-30 Fujisawa Pharmaceutical Co Percutaneous absorbent preparation
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
SE9401197D0 (sv) 1994-04-11 1994-04-11 Astra Ab Active compounds
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US6124313A (en) 1994-07-28 2000-09-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine azolidinones
JP3031280B2 (ja) 1994-08-19 2000-04-10 東陶機器株式会社 便器洗浄装置
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
FR2746800B1 (fr) * 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
JP3031280U (ja) 1996-05-15 1996-11-22 サン トップ コンピューター システムズ コーポレーション 線性ｃｃｄバーコードの読取り装置
KR20000065219A (ko) 1996-05-20 2000-11-06 마르크 젠너 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
CN1234031A (zh) 1996-09-04 1999-11-03 辉瑞大药厂 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
WO1998020858A1 (en) 1996-11-12 1998-05-22 Pharmacia & Upjohn Ab COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF
CN1123345C (zh) * 1997-02-17 2003-10-08 奥坦纳医药公司 治疗ards或irds的组合物
SE9700661D0 (sv) * 1997-02-25 1997-02-25 Astra Ab New compounds
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
US6160119A (en) 1997-05-28 2000-12-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fused dihydropyrans
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
HUP0001555A3 (en) 1997-10-30 2001-01-29 Altana Pharma Ag Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
PL196163B1 (pl) * 1997-12-08 2007-12-31 Altana Pharma Ag Nowa postać leku do podawania doustnego związków aktywnych nietrwałych w środowisku kwaśnym, zastosowanie jednostek związku aktywnego do wytwarzania leku do podawania doustnego oraz sposób wytwarzania nowej postaci leku do podawania doustnego
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
DE69937343T2 (de) * 1998-05-07 2008-07-24 Corixa Corp., Seattle Adjuvanszusammensetzung und methoden zu deren verwendung
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000006121A1 (de) 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
JP2002523452A (ja) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション 肺疾患の治療方法
AU5970199A (en) 1998-08-31 2000-03-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
PT1115725E (pt) 1998-09-23 2003-06-30 Altana Pharma Ag Tetra-hidropiridoeteres
AU5758199A (en) 1998-09-29 2000-04-17 Fujisawa Pharmaceutical Co., Ltd. Novel salts of pyridopyrazine compound and crystals thereof
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
WO2000020033A1 (en) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
WO2000026217A1 (en) 1998-11-03 2000-05-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazonaphthyridines
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
DE19858331A1 (de) 1998-12-17 2000-06-21 Boehringer Ingelheim Pharma Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
DE60015098T2 (de) 1999-03-10 2006-02-02 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
CN1126468C (zh) 1999-04-08 2003-11-05 王力田 一种黑玉米秸秆饮料及其制备方法
US6503923B1 (en) * 1999-04-17 2003-01-07 Altana Pharma Ag Haloalkoxy imidazonaphthyridines
KR100328972B1 (ko) 1999-04-23 2002-03-20 서경배 피부 유용 활성성분을 함유한 화장료 또는 피부도포용 의약품 조성물의 제조방법 및 이러한 방법에 의해 제조된 화장료 또는 피부도포용 의약품 조성물
US6498173B1 (en) * 1999-05-04 2002-12-24 Altana Pharma Ag Synergistic combination comprising roflumilast and a pde-3 inhibitor
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
ATE399554T1 (de) 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
ATE320800T1 (de) * 1999-08-21 2006-04-15 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
AU776920B2 (en) 1999-10-25 2004-09-23 Sony Corporation Method for managing content data
US7076437B1 (en) 1999-10-29 2006-07-11 Victor Levy Process for consumer-directed diagnostic and health care information
MXPA02004220A (es) * 1999-10-29 2002-10-17 Smithkline Beecham Corp Metodo para administrar un inhibidor de fosfodiesterasa 4.
US6985188B1 (en) 1999-11-30 2006-01-10 Thomson Licensing Video decoding and channel acquisition system
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2003522165A (ja) 2000-01-31 2003-07-22 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なピリミジンカルボキサミド
US6379682B1 (en) * 2000-02-07 2002-04-30 Color Access, Inc. Clear water-in-oil emulsions
US20030207845A1 (en) * 2001-02-08 2003-11-06 Keating Elizabeth T. Method and compositions for treating an inflammatory disease
WO2001060358A1 (en) 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
JP2004500404A (ja) * 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
CA2407780A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
EP1161950A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6528527B2 (en) 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
CA2430824C (en) 2000-12-07 2012-05-08 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
DK1341524T3 (da) 2000-12-07 2012-01-16 Nycomed Gmbh Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
EP1341528B1 (en) 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
ATE472319T1 (de) 2001-02-15 2010-07-15 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
AU2002254036A1 (en) 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
FR2821745B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6702796B2 (en) 2001-03-26 2004-03-09 The Procter & Gamble Company Absorbent interlabial device having an improved tab
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
EP1397135B1 (en) 2001-05-25 2006-12-06 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6756392B2 (en) * 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04011335A (es) 2002-05-16 2005-07-01 Pharmacia Corp Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
US20030215498A1 (en) 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
BR0311339A (pt) 2002-05-28 2005-03-22 Altana Pharma Ag Preparação farmacêutica topicamente aplicável
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
EP2942359A1 (en) * 2002-07-19 2015-11-11 AbbVie Biotechnology Ltd Treatment of TNF alpha related disorders
US20030018071A1 (en) * 2002-08-09 2003-01-23 Rennard Stephen I. Method and compositions for treating fibrotic diseases
PL372926A1 (en) 2002-08-10 2005-08-08 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003259417A1 (en) 2002-09-04 2004-03-29 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
WO2004047829A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag New synergistic combination comprising roflumilast and formoterol
KR20050094810A (ko) * 2002-11-27 2005-09-28 알타나 파마 아게 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
AU2003302881A1 (en) 2002-12-11 2004-06-30 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
MXPA05008193A (es) 2003-01-30 2006-05-25 Ethypharm Sa Particulas con revestimiento que oculta el sabor, proceso para la preparacion de las mismas y tabletas orodispersables que contienen dichas particulas revestidas.
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
PL1610787T3 (pl) * 2003-03-28 2008-07-31 Astrazeneca Ab Synergiczna kombinacja zawierająca roflumilast i środek antycholinergiczny wybrany z soli tiotropium do leczenia chorób układu oddechowego
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
US20050026883A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2007501810A (ja) 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
EP1673064A1 (en) 2003-08-28 2006-06-28 Sandoz AG Pharmaceutical composition comprising anticonvulsant with taste mask coating
EP1670742A1 (en) 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
CA2544611A1 (en) 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
MXPA06004499A (es) 2003-10-21 2006-06-27 Pharmacia Corp Metodo para el tratamiento o la prevencion de inflamacion respiratoria con un inhibidor de ciclooxigenasa 2 en combinacion con un inhibidor de fosfodiesterasa 4 y sus composiciones.
WO2005058892A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US7562356B2 (en) * 2004-09-22 2009-07-14 Hewlett-Packard Development Company, L.P. Automatically resolving patch dependencies for a path bundle
US7884059B2 (en) * 2004-10-20 2011-02-08 Afton Chemical Corporation Oil-soluble molybdenum derivatives derived from hydroxyethyl-substituted Mannich bases
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006094640A2 (en) 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
MX2009000148A (es) 2006-07-07 2009-10-26 Kalypsys Inc Inhibidores heteroaril biciclicos de fosfodiesterasa 4.
USD580547S1 (en) * 2007-07-31 2008-11-11 Nycomed Gmbh Tablet
JP5271070B2 (ja) 2008-12-24 2013-08-21 エスアイアイ・プリンテック株式会社 ヘッドチップ、液体噴射ヘッド及び液体噴射装置
US20120052122A1 (en) 2010-08-26 2012-03-01 Nycomed Gmbh Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
EA201391643A1 (ru) 2011-05-06 2014-07-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Составы с замедленным высвобождением парацетамола
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure

Also Published As

Publication number Publication date
CN1635909B (zh) 2012-09-05
AR038527A1 (es) 2005-01-19
ES2384378T3 (es) 2012-07-04
NO332844B1 (no) 2013-01-21
US20050159492A1 (en) 2005-07-21
CN1635909A (zh) 2005-07-06
EP1478399B1 (en) 2012-03-21
KR101386843B1 (ko) 2014-04-17
PL226401B1 (pl) 2017-07-31
AU2003206924B2 (en) 2008-11-13
CY1114210T1 (el) 2016-08-31
ATE550038T1 (de) 2012-04-15
EA200401019A1 (ru) 2005-04-28
ES2424634T3 (es) 2013-10-07
US8431154B2 (en) 2013-04-30
IS7410A (is) 2004-08-18
ME00566B (me) 2011-12-20
CA2475923C (en) 2013-06-18
KR20100103729A (ko) 2010-09-27
TW200303768A (en) 2003-09-16
US20150290178A1 (en) 2015-10-15
CN102764242B (zh) 2016-09-07
KR101253033B1 (ko) 2013-04-11
JP4163120B2 (ja) 2008-10-08
US20140031397A1 (en) 2014-01-30
MXPA04005759A (es) 2004-09-10
SI2258394T1 (sl) 2013-09-30
US20110060016A1 (en) 2011-03-10
US20110251244A1 (en) 2011-10-13
US20140031396A1 (en) 2014-01-30
RS73604A (sr) 2007-02-05
TNSN04124A1 (en) 2007-03-12
JP2005517724A (ja) 2005-06-16
IL162843A0 (en) 2005-11-20
US20150290180A1 (en) 2015-10-15
KR20040084926A (ko) 2004-10-06
MA27100A1 (fr) 2004-12-20
BR0307739A (pt) 2005-01-25
EP2258394B1 (en) 2013-05-15
US20130345265A1 (en) 2013-12-26
CA2475923A1 (en) 2003-08-28
ECSP045238A (es) 2004-09-28
GEP20074079B (en) 2007-03-26
ME00566A (en) 2011-12-20
PL370595A1 (en) 2005-05-30
NZ535197A (en) 2006-11-30
PT2258394E (pt) 2013-07-23
DK2258394T3 (da) 2013-08-19
US7951397B2 (en) 2011-05-31
US20150290179A1 (en) 2015-10-15
RS52548B (sr) 2013-04-30
CN102764242A (zh) 2012-11-07
EP1478399A1 (en) 2004-11-24
IL237196A0 (en) 2015-03-31
MY140561A (en) 2009-12-31
US20130131123A1 (en) 2013-05-23
EA008219B1 (ru) 2007-04-27
US20060269600A1 (en) 2006-11-30
DK1478399T3 (da) 2012-06-25
UA84266C2 (uk) 2008-10-10
AU2003206924A1 (en) 2003-09-09
PE20030823A1 (es) 2003-10-11
US9468598B2 (en) 2016-10-18
EP2258394A1 (en) 2010-12-08
IL162843A (en) 2015-03-31
PT1478399E (pt) 2012-05-30
WO2003070279A1 (en) 2003-08-28
HK1077752A1 (en) 2006-02-24
CY1112811T1 (el) 2016-02-10
TWI363636B (en) 2012-05-11
SI1478399T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
NO20043904L (no) Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
DK1564210T3 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
PT1501534E (pt) Formulacoes farmaceuticas
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20033785L (no) Farmasöytisk formulering
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
DE60307677D1 (de) Dispergierbare pharmazeutische zusammensetzungen
NO20035627D0 (no) Farmasöytisk formulering
NO20040254L (no) Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60328119D1 (de) Pharmazeutische zubereitungen enthaltend modafinil
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DK1849468T3 (da) Farmaceutisk sammensætning omfattende roflumilast og levocetirizin
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
NO20042153L (no) Piperidin-2-on-derivatforbindelser og farmasoytisk sammensetning omfattende samme som aktiv ingrediens
SE0201660D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA AB, SE

MK1K Patent expired